EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
The EAHP EU Monitor is a weekly round up of news relevant to hospital pharmacy in Europe.
You can subscribe to the EAHP EU Monitor here.
.jpg)
The The European Association of Hospital Pharmacists (EAHP) is pleased to announce the Malta Association of Hospital Pharmacists (MAHP) and the Romanian Association of Hospital Pharmacists (ANFSR) as its newest members following the annual General Assembly of EAHP in Athens (14th-15th June 2013).
At the first-ever “International Summit on Medicine Shortages” hosted by the International Pharmaceutical Federation, and co-hosted by the Canadian Pharmacists Association 6 primary recommendations were agreed to help alleviate problems being caused by the common global phenomena of medicines shortages.
The agreed recommendations were:
1. Each country should establish a publicly accessible means of providing information on shortages;
2. A global process to determine the list of critical/vulnerable products should be developed;
3. All procurers of medicines are urged to move towards active procurement processes that assure the continuity of supply of quality medicines;
4. All countries are encouraged to remove unnecessary variability of regulatory practices within and between countries;
5. All countries should investigate the potential to establish a national body charged with gathering and sharing information about demand for, and supply of, medicines within their jurisdiction; and,
6. All countries are encouraged to develop evidence-based risk mitigation strategies which might include strategic buffer stockpiles, contingency plans, pandemic planning and capacity redundancy appropriate to their national needs.
More information here.
In advance of a 1 July 2013 Falsified Medicines Directive implementation deadline, the European Commission has granted an exemption from some regulatory requirements to pharmaceutical companies based in the USA who wish to export products to Europe.
Amongst the many requirements of the 2011 Directive on Falsified Medicines, is a “listing” system of countries from outside the EU wishing to export pharmaceutical products into Europe. The listing system is designed to give assurance that products from outside the EU have adhered to the same principles of good manufacturing as would have been the case were they manufactured within the EU.
The USA’s Food and Drug Administration (FDA) had requested that the European Commission consider its own manufacturing requirements and regulatory regime to be at least equivalent to that prevailing in Europe – a request which the Commission has now granted.
The ‘listing” of the USA has helped to alleviate some of the concerns that the new system could unintentionally add to medicines shortage problems by preventing EU countries from importing medicines from outside the European area.
The USA now joins Japan, Switzerland and Australia in benefitting from this special listing category.
More information here.
More information about the Falsified Medicines Directive here.
EJHP: Multisite analysis of missed doses in antibioticsThe online first edition of the EJHP has published an original research article on missed doses of antibiotics administered in hospital care.
Aiming to quantify the incidence of missed antibiotic doses in acute hospitals and identify the underlying reasons, the study made use of data from electronic prescribing and medicines administration systems (EPMAS), and had as an objective, to establish the feasibility of determining a minimal acceptable range for missed antibiotic doses.
More information here.
